Slide 1: Investor Presentation Financial Year 2013/14
For personal use only Investor Presentation Financial Year 2013/14
Slide 2: Disclaimer & Regulatory Disclosure
Disclaimer & Regulatory Disclosure This document has been prepared as a summary Some of the statements contained in this release are forward-looking statements. Forward looking statements include but are not limited to, statements concerning only, and does not contain all information about the estim
Slide 3: Group: Seven years of continuous growth
Group Seven years of continuous growth For personal use only Unit sales growth Revenue growth ($’ millions) CAGR 36%pa CAGR 39%pa SomnoMed Investor Presentation – Page 3
Slide 4: APAC – New sales levels reached
Group APAC – New sales levels reached For personal use only APAC quarterly unit sales SomnoMed Investor Presentation – Page 4
Slide 5: USA – Initiatives and changes return company to higher growth
Group USA – Initiatives and changes return company to higher growth For personal use only USA quarterly unit sales SomnoMed Investor Presentation – Page 5
Slide 6: Europe – Extraordinary growth linked to expansion of business
Group Europe – Extraordinary growth linked to expansion of business For personal use only Europe quarterly unit sales SomnoMed Investor Presentation – Page 6
Slide 7: Balanced business between USA, Europe and APAC
Group Balanced business between USA, Europe and APAC For personal use only Share of units sold by global region 11% 11% 12% 27% 31% 36% 61% 58% 53% USA Europe APAC SomnoMed Investor Presentation – Page 7
Slide 8: Financial Summary Profit and Loss
Financial Summary Profit and Loss For personal use only Financial Summary ($000’s) 08/09 09/10 10/11 11/12 12/13 13/14 Revenue 7,737 10,714 12,335 15,246 18,489 25,894 Net Average Sales Per Unit (Direct MAS – Actual $) 641 562 536 535 562 639 Gross Margin 4,059 6,084 8,176 10,357 12,267 16,810 Group
Slide 9: Consistent underlying profits after investments made 2013/14
Financial Consistent underlying profits after investments made 2013/14 For personal use only 2013/14 Financial Summary ($000’s) Underlying EBITDA* Total Year 1st Half 2nd Half Revenues 25,894 12,553 13,341 Investments made in FY14: Investments in Medical Capabilities (MAB, CMO, 1,850 915 935 Managed
Slide 10: Net Financial Result 2013/14
Financial Net Financial Result 2013/14 For personal use only Financial Summary Net profit after taxation 2012/13 2013/14 Operating profit before corporate, research and business development 3,227,060 3,697,689 expenses, non cash items and income tax Share of profit of associated company 63,601 – Cor
Slide 11: Guidance 2014/15: continuation of accelerating growth
Guidance 2014/15 SomnoMed expects continuation of accelerating growth 2014/15 For personal use only Unit sales to grow by 26.5% Revenue to grow by 25% in 2014/15 to 55,000 units in 2014/15 to $32.5M* Units Revenue ($’ millions) *constant exchange rates SomnoMed Investor Presentation – Page 11
Slide 12: Guidance 2014/15 Growth Driver: demand for custom made oral appliances
Guidance 2014/15 Growth Driver 1 Demand for custom made oral appliances as alternative treatment for sleep disordered breathing is expanding worldwide For personal use only • Increased awareness of sleep disordered breathing • Different countries adopt COAT ™ at different speeds and simpler home sle
Slide 13: Broadening the SomnoDent product line
Guidance 2014/15 Growth Driver 2 Broadening the SomnoDent® product line For personal use only SomnoDent Fusion1 Flex SomnoDent Herbst SomnoDent Flex SomnoDent G2 SomnoDent Herbst Advance1 Standard SomnoDent Herbst SomnoDent SomnoDent Classic Herbst Advance1 Other SomnoDent Compliance Control3 Somtab
Slide 14: Entry into new markets
Guidance 2014/15 Growth Driver 3 Entry into new markets Established Markets Emerging Markets New Markets For personal use only Entry 2004 - 2008 Entry 2009 - 2013 Entry 2014 - 2015 Asia-Pacific Asia-Pacific Asia-Pacific New Zealand (2009) Japan (2009) Singapore (2010)* Australia Malaysia (2010)* Kor
Slide 15: Profits to double in 2014/15 – EBITDA range of $2.0 to $4.0 Million
Guidance 2014/15 Profits to double in 2014/15 – EBITDA* range of $2.0 to $4.0 Million For personal use only • The financial year 2014/15 will start to show the earnings strength $4.0M of SomnoMed • After investing approximately $2m in FY14 in building the base for medical in USA, this division will
Slide 16: Contact details
For personal use only Executive Chairman and CEO | Dr Peter Neustadt Chief Financial Officer | Mr Neil Verdal–Austin Address | Level 3 20 Clarke Street Crows Nest NSW 2065 Australia Telephone | +61 (2) 9467 0400 Website | www.somnomed.com.au